Financial Data and Key Metrics Changes - Relmada closed 2025 with a cash balance of $93 million, an increase from approximately $45 million at the end of 2024, primarily due to a successful $160 million private financing [19][20] - Research and development expenses for Q4 2025 totaled $8.1 million, a decrease from $11 million in Q4 2024, driven by reduced study costs from completed trials [20] - General and administrative expenses increased to $12.3 million in Q4 2025 from $8.1 million in Q4 2024, primarily due to higher compensation costs [21] - The net loss for Q4 2025 was $19.9 million, or $0.27 per share, compared to a net loss of $18.7 million, or $0.62 per share, in Q4 2024 [23] Business Line Data and Key Metrics Changes - The NDV-01 program reported a 12-month complete response rate of 76% in high-risk NMIBC patients, with an 80% response rate in the BCG unresponsive population [11][12] - Sepranolone is preparing for a proof of concept study in Prader-Willi syndrome, with plans to initiate in mid-2026 [18] Market Data and Key Metrics Changes - The U.S. market for intermediate-risk bladder cancer patients is estimated at 70,000-75,000 annually, while the second-line treatment for BCG unresponsive patients is about 5,000 annually [13][15] - Only 35% of intermediate-risk patients currently receive adjuvant therapy, indicating significant market potential for new treatments [53] Company Strategy and Development Direction - The company plans to initiate the phase 3 RESCUE program for NDV-01 in mid-2026, with two registrational pathways focusing on intermediate-risk and BCG unresponsive patients [5][13] - The strategic focus includes enhancing clinical data presentation and establishing a robust supply chain for sepranolone [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical programs and long-term prospects, emphasizing the importance of execution in the upcoming RESCUE program [24][57] - The company aims to redefine the standard of care in bladder cancer with NDV-01, leveraging its unique sustained-release formulation [17] Other Important Information - The company has strengthened its development team with the appointment of Dr. Raj S. Pruthi as Chief Medical Officer-Urology [6] - A successful $160 million private financing was completed, providing capital through 2029 [8][20] Q&A Session Summary Question: Will additional data from the phase two study be presented? - Management confirmed that updated 12-month data will be presented at AUA and plans to share data every three months [26][29] Question: How will the company ensure that second-line patients are accurately categorized? - The company will limit prior therapy lines to two and will monitor patient characteristics closely to ensure accurate categorization [27][30] Question: What is the expectation for enrollment cadence across the studies? - Management indicated that the unique in-office profile of NDV-01 could serve as a recruitment advantage, despite a crowded market [34][35] Question: What is the FDA's requirement for follow-up duration before submitting the NDA? - The FDA has not stipulated a minimum follow-up duration but is interested in the totality of the data regarding response and durability [36] Question: How do the complete response rates compare between phase 2 and phase 3? - Management expects to exceed the benchmark of 75% two-year recurrence-free survival based on the statistics structured for the trial [42]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 grew 12% to a record $6.6 million, and for the full year, revenue increased 13% to $22.7 million, another company record [6][22] - Gross margin for Q4 2025 increased to 91.4% compared to 91.1% in Q4 2024, reflecting the strength of the software-driven SaaS model [6][24] - The company achieved annual operating profitability for the first time since going public, with net income of $1.3 million and EPS of $0.06 [7][22] - Adjusted EBITDA for Q4 2025 was a record $1.9 million, and for the full year, it reached $2.6 million, nearly five times the previous year [8][22] Business Line Data and Key Metrics Changes - SaaS revenue for Q4 2025 grew 12% to $6.62 million, representing over 99% of total revenue [24] - The average price per transaction increased by 25% in Q4 2025 compared to the previous year, indicating pricing power for the company's unique product [18] Market Data and Key Metrics Changes - The banking and lending sector continues to grow, with year-over-year growth nearly doubling, while retail saw a decline of 1% [37] - The automotive sector experienced a significant growth of 125% year-over-year, driven by channel partners [68] Company Strategy and Development Direction - The company aims to build a durable, differentiated, high-margin business by expanding with existing customers and onboarding new ones while maintaining disciplined execution [20] - There is a focus on diversifying into new verticals such as title insurance, automotive, specialty finance, background screening, logistics, and digital account security [18][17] - The company is refining its sales team and channel partner program to drive significant growth across various verticals [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, particularly in banking, which is less dependent on interest rates or consumer confidence [18] - The company is well-positioned to capitalize on new opportunities as interest rates change, with expectations of continued revenue growth and improved profitability [35] Other Important Information - The company ended the year with $9.6 million in cash and a strong debt-free balance sheet, reflecting strong cash generation from operations [7][33] - The company has been recognized as a leader in identity verification in financial services by the IDC MarketScape report [17] Q&A Session Summary Question: What was the performance of the bank lending channel in Q4? - The banking and lending sector continues to grow, with nearly double year-over-year growth, while retail was down 13% compared to Q4 2024 [37][39] Question: How does the pipeline look for new customers in 2026? - The pipeline looks strong, driven by the new desktop solution and partnerships, particularly with mid-sized credit unions and banking institutions [40] Question: What is the status of the relationship with Ping Identity? - The company needs to improve its channel partnership with Ping Identity to facilitate better integration and sales [45] Question: What are the growth expectations for 2026? - While the company does not provide formal guidance, there is built-in growth from existing clients, and the focus is on how quickly implementations can occur [60] Question: What metrics can be shared regarding the automotive sector? - Automotive revenue grew 125% year-over-year, with significant potential for further growth through channel partners [68]

electroCore (NasdaqCM:ECOR) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Speaker5Greetings, and welcome to the electroCore fourth quarter and full year 2025 earnings conference call. At this time, all participants have been placed in a listen-only mode. Please make sure to mute yourself. Question and answer session will follow the formal presentation. A reminder, this conference call is being recorded. Earlier today, electroCore published results for the fourth quarter and full year ended December 31, 2 ...

Financial Data and Key Metrics Changes - The company achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024, with fourth quarter revenue of $1.5 million, representing a 92% increase over the prior year period [3][9] - Gross profit for the fourth quarter was $1 million, or 69% of revenue, compared to $0.4 million, or 46% of revenue in the prior-year quarter, marking a 188% increase and a 23 percentage point improvement in gross margin [10] - Operating expenses totaled $3.9 million for the fourth quarter, up from $3.5 million in the prior year quarter, while for the full year, operating expenses totaled $15.2 million, compared to $15.5 million in the prior year period [11][12] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by an increase in surgical procedures across both the Catamaran and SImmetry+ platforms, particularly in the second half of 2025, led by new physician users [3][9] - The company hosted 24 physicians in targeted training sessions for both platforms during the fourth quarter, supporting clinical engagement [4] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for the next generation SImmetry+ SI joint fusion system, enhancing its ability to serve a broader range of surgeon preferences and patient anatomies [4][8] - The company expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its global estate to 29 issued U.S. patents and 31 pending applications [7] Company Strategy and Development Direction - The company is focused on advancing its market position with increased adoption across its expanding portfolio, leveraging regulatory and market momentum to drive broader commercial uptake [8] - The company aims to optimize its cost structure and scale operations to extend market reach more efficiently, with plans to accelerate revenue growth and deliver sustained value [8][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet and exceed expectations in 2026, citing strong adoption momentum and an engaged pipeline [22][24] - The company believes that its multi-product portfolio will address various physician and patient needs, enhancing its competitive position in the market [30] Other Important Information - The company strengthened its balance sheet through a $2.85 million PIPE financing and a subsequent private placement of senior convertible notes for gross proceeds of $4.3 million, providing additional runway for commercial and clinical priorities [5][12] Q&A Session Summary Question: How representative is the Q4 operating expense rate for 2026? - Management indicated that the Q4 operating expense of $3.9 million is a better baseline moving forward into 2026, with some higher integration costs falling out in Q4 [18][19] Question: What is the revenue outlook for 2026? - Management did not provide specific projections but expressed excitement about adoption momentum and the impact of new product launches on revenue growth [22][24][28] Question: What are the key drivers for revenue growth in 2026? - Management highlighted the multi-product portfolio and the commercial expansion as key drivers for revenue growth, with a focus on addressing various physician needs [30][39]

Financial Data and Key Metrics Changes - Curis reported a net income of $19.4 million or $1.23 per share for Q4 2025, compared to a net loss of $9.6 million or $1.25 per share for Q4 2024, primarily due to a $27.2 million one-time non-cash gain from the sale of Erivedge [10] - For the year ended December 31, 2025, the net loss was $7.6 million or $0.58 per share, a significant improvement from a net loss of $43.4 million or $6.88 per share in 2024 [10] - Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, and for the year, they were $28.3 million compared to $38.6 million in 2024 [11] - General and administrative expenses also decreased to $2.9 million in Q4 2025 from $3.4 million in Q4 2024, totaling $14 million for the year compared to $16.8 million in 2024 [11] Business Line Data and Key Metrics Changes - The Take Aim Lymphoma study in primary CNS lymphoma is progressing well, with expectations for accelerated submissions in the U.S. and Europe [4] - Initial data from the ongoing AML triplet study showed that 5 of 8 evaluable patients achieved MRD conversion, indicating potential effectiveness of the treatment combination [8][9] Market Data and Key Metrics Changes - The company is focusing on expanding emavusertib studies into additional NHL subtypes, particularly CLL, where current treatments have limitations [5][6] - The company is prioritizing NHL studies over AML due to resource allocation and the potential for registrational approval in PCNSL [14][15] Company Strategy and Development Direction - Curis aims to improve the treatment paradigm for CLL by combining emavusertib with BTKI regimens, targeting deeper responses and potential complete remission [6][39] - The company is actively engaging with clinical sites in the U.S. and Europe to advance its studies and expects to present initial data at the ASH annual meeting in December [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and the potential for significant advancements in treatment options for patients with CLL and NHL [4][9] - The company anticipates no meaningful revenue in 2026 due to the cessation of cash flows from Erivedge, but is confident in its financial position to support operations into the second half of 2027 [12][27] Other Important Information - Curis has secured initial gross proceeds of $20.2 million from financing, which will support its operations and clinical trials [12] Q&A Session Summary Question: How is the company prioritizing trial progress between pivotal PCNSL versus CLL and AML? - Management indicated that resources are being prioritized towards NHL, particularly PCNSL, while CLL is in the early stages of study [14][15] Question: Can you provide updates on PCNSL enrollment? - Management confirmed that enrollment is on track, with expectations for full enrollment within 12-18 months [22] Question: Should revenue modeling reflect no meaningful revenue for 2026? - Management confirmed that there will be no meaningful revenue, as cash flows from Erivedge have ended [27][28] Question: What data should be expected at ASH 2026 for CLL? - Management stated that they hope to present meaningful data regarding the treatment's effectiveness, focusing on deepening patient responses [35][36]

Financial Data and Key Metrics Changes - In Q3 2026, revenues were $329.1 million, down from $335.4 million in the prior year, reflecting a decrease of approximately 1% [20] - Adjusted operating loss was $24.3 million compared to $20.9 million in the prior year, while adjusted EBITDA was approximately break-even compared to $6 million in the prior year [20][21] - Net loss increased to $3.5 million from $1.3 million in the prior year, with adjusted loss per diluted share rising to $0.15 from $0.05 [21] Business Line Data and Key Metrics Changes - Children's Book Publishing and Distribution revenues decreased 3% to $197.6 million, with adjusted operating profit improving to $8.9 million from $7.6 million [21] - Book Fairs revenue increased 2% to $113.3 million, driven by higher revenue per fair, while Book Clubs revenues were relatively flat at $14.6 million [22] - Trade Publishing revenues fell 10% to $69.7 million, impacted by the timing of major releases compared to the prior year [22] Market Data and Key Metrics Changes - International segment revenues were $58.7 million, down from $59.3 million a year ago, with a decline attributed to publication timing [25] - The Australian and UK markets showed strong contributions, benefiting from operational improvements [18] Company Strategy and Development Direction - The company completed a sale leaseback transaction generating over $400 million in net proceeds, aimed at optimizing the balance sheet and enhancing shareholder value [4][19] - A new $300 million share repurchase authorization was announced, including a $200 million modified Dutch auction tender offer [5][29] - The company aims to stabilize its education segment and return to growth in fiscal 2027, focusing on aligning products with district and school needs [15][17] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed fiscal 2026 adjusted EBITDA guidance of $146 million to $156 million, despite the impact of the sale leaseback transactions [31] - The company expects a return to profitability in Q4, driven by improved performance in Book Fairs and Education segments [32] - Management expressed confidence in achieving revenue growth in the fourth quarter, particularly from Book Fairs, while acknowledging challenges in the Trade segment due to prior year comparisons [36][38] Other Important Information - The company established long-term net leverage targets of 2-2.5 times Adjusted EBITDA, balancing growth investments with shareholder returns [28] - Free cash flow in Q3 was $407 million, reflecting proceeds from the sale leaseback transactions [27] Q&A Session Summary Question: Confidence in achieving 2% growth in Q4 - Management highlighted Book Fairs as a major growth factor, with positive initial indications for the quarter [36][37] Question: Sales pipeline for education solutions - Management expects strong performance in summer reading and other educational products, with improving sales pipeline trends [40][43] Question: Adjusted EBITDA guidance for Q4 - Management expressed confidence in achieving the guidance due to cost mitigation actions and the seasonal nature of the business [45][47] Question: Performance of the entertainment segment - Management noted an increase in green lighting activity and anticipated steady growth in the entertainment segment [48][49]

United States Antimony (NYSEAM:UAMY) Q4 2025 Earnings call March 19, 2026 04:15 PM ET Company ParticipantsGary C. Evans - Chairman and CEOJoe Bardswich - Board Member, EVP, and Chief Mining EngineerJonathan Miller - VP of Investor RelationsMelissa Pagen - President and COORichard Isaak - SVP and CFOOperatorGreetings. Welcome to the U.S. Antimony Corporation Fiscal Year 2025 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer sessio ...

United States Antimony (NYSEAM:UAMY) Q4 2025 Earnings call March 19, 2026 04:15 PM ET Company ParticipantsGary C. Evans - Chairman and CEOJoe Bardswich - Board Member, EVP, and Chief Mining EngineerJonathan Miller - VP of Investor RelationsMelissa Pagen - President and COORichard Isaak - SVP and CFOOperatorGreetings. Welcome to the US Antimony Corporation fiscal year 2025 financial and operating results conference call. At this time, all participants are in a listen-only mode. A question-and-answer session ...

Financial Data and Key Metrics Changes - Revenues for 2025 were $39.3 million, up 163% from the previous year, driven by price increases in antimony and zeolite sales [9] - Gross profit increased by $6.4 million or 185% year-over-year, with gross margin growing from 23% to 25% [10] - Net loss increased from $1.7 million in 2024 to $4.3 million in 2025, including $6.7 million of non-cash expenses [10] - Cash position rose to $91.3 million at the end of 2025, compared to $18.2 million at the end of 2024 [11] - Working capital increased by $27.9 million to $44.6 million, primarily due to increases in cash, inventory, and U.S. Treasury securities [11] Business Line Data and Key Metrics Changes - Antimony sales increased significantly due to price hikes, while zeolite sales rose from both price and volume increases [9] - The company became fully vertically integrated in its antimony division in 2025, enhancing procurement and processing capabilities [12] - The antimony inventory grew from 78 tons at the end of 2024 to 465 tons at the end of 2025, with 17% sourced from the company-owned mine [11] Market Data and Key Metrics Changes - The company announced a $248 million contract with the U.S. government for antimony ingots, expected to deliver approximately $75 million in fiscal 2026 [4] - A new $106.7 million industrial antimony contract was secured, enhancing the company's market position [4] Company Strategy and Development Direction - The company is focusing on growth, diversification, and sustainability, with plans to expand its operations in critical minerals [13] - A new hydromet facility is being constructed in Idaho to process antimony, with funding support from the U.S. Department of Defense [13] - The company aims to leverage its mining claims in Alaska as a central part of its future operations [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the volatility in the antimony market but expressed confidence in meeting contractual obligations due to increased inventory [66] - The company anticipates a bumpy financial year in 2026 but maintains a revenue guidance of $125 million based on existing contracts [66] - There is a strong focus on securing additional government funding for various projects, reflecting the company's strategic alignment with national security priorities [62] Other Important Information - The company has dual-listed its securities on both the NYSE American and the NYSE Texas, enhancing visibility and credibility [54] - Institutional ownership has grown significantly, with 222 institutional holders now, up from 48 in Q4 2024 [56] Q&A Session Summary Question: How do you see the production mix evolving over the next 12-18 months? - The company aims to mine its own antimony, which is cheaper than purchasing from external sources, enhancing profit margins and reliability [78] Question: Are you able to switch vendors to avoid equipment delays? - Unfortunately, the specialized equipment ordered cannot be sourced from other vendors, necessitating patience for delivery [81] Question: Can you provide an update on ore shipments from Alaska? - The geologist estimates a potential output of 1,000 tons a month, but the company is cautiously optimistic and will have clearer insights by summer [82] Question: Have there been talks with defense firms about replenishing munitions supplies? - The company is already supporting the U.S. government through a $248 million contract and maintains ongoing discussions regarding additional needs [88] Question: What is the progress at Thompson Falls regarding the expansion? - The expansion is delayed until May due to third-party supplier issues, but the company is actively working on it and expects to see results in the future [63][64]

Summary of Orion Engineered Carbons Conference Call Company Overview - **Company**: Orion Engineered Carbons (Ticker: OEC) - **Headquarters**: Luxembourg, executive offices in Spring, Texas - **Industry**: Carbon black manufacturing - **Market Position**: Leading global manufacturer and supplier of carbon black products, primarily rubber carbon black and specialty carbon black [1][2] Financial Highlights - **Shares Outstanding**: Approximately 56 million - **Market Cap**: $280 million - **Net Debt**: $918 million - **Enterprise Value**: $1.2 billion - **Recent Revenue**: EUR 1.8 billion - **EBITDA**: EUR 248 million - **Free Cash Flow**: EUR 55 million [2][9] Strategic Focus - **Free Cash Flow Generation**: Identified as the primary financial priority for 2026 and beyond, with a focus on improving cash flow through working capital actions and reduced capital expenditures [7][13] - **Debt Reduction**: Aiming to reduce net debt, which was approximately 3.7x net debt to EBITDA at year-end [14][41] Market Dynamics - **Rubber Carbon Black**: Represents two-thirds of the business, with a focus on tire applications (OEM and replacement tires) and mechanical rubber goods [16][17] - **Specialty Carbon Black**: Accounts for one-third of the business, with applications in polymers, coatings, and batteries [19][20] - **Growth Drivers**: Traditional growth driven by miles driven, tire production, and vehicle production, with emerging trends in sustainability and electric vehicle (EV) mobility [18][23] Pricing and Contracts - **Pricing Strategy**: A variable price surcharge of up to 25% was introduced, primarily affecting the specialty side of the business, as most rubber customers are under annual contracts [49][50] - **Market Conditions**: Anticipated challenges in pricing negotiations for 2026 due to high imports and late negotiation cycles [40][41] Production Capacity and Regional Focus - **Capacity Utilization**: Estimated at mid-80s percentage for effective capacity utilization, with regional dynamics affecting supply [56] - **Local Supply Importance**: Emphasized the critical nature of being a local supplier to tire manufacturers in North America, especially given the lack of new carbon black capacity being built in the U.S. [35][36] Environmental and Regulatory Considerations - **EPA Investments**: Significant investments made in compliance with EPA regulations, with competitors still facing these costs, potentially benefiting Orion in terms of pricing and market position [37][38] Future Outlook - **2026 Projections**: Expected EBITDA between EUR 160 million and EUR 200 million, with free cash flow projected at EUR 25 million to EUR 50 million [42] - **Market Recovery**: Anticipated improvement in market conditions and pricing environment, driven by reduced capacity in the market and better economic indicators [34][41] Additional Insights - **Customer Relationships**: Strong relationships with global tire customers are expected to provide opportunities for spot volume [30] - **Safety and Reliability**: Achieved record safety performance, significantly better than industry average, contributing to operational reliability [39] This summary encapsulates the key points discussed during the conference call, highlighting Orion Engineered Carbons' market position, financial performance, strategic focus, and outlook for the future.